____ is a clinical stage biotechnology ( biopharmacetical ) company focus on cell therapy and soluble protein drugs for hematological cancers and solid tumors. ___ is committed to the benefit of human health through technological innovation and market transformation.
Beike and Abigene co-founded _____ through M&A and restructing.
Founded on the vision that MAR is a new generation of specific antibodies against the "MHC" of binding antigenic peptides that can identify the cell surface and intracellular targeting compared with conventional CAR , we are developing MAR technology platform and applications in cell therapy and soluble protein drugs to recognize and kill cancer cells , which occupies an important position in the international immunotherapy and has broad application prospects.
Innovative core technology
Rapid clinical translation
Global development and partnering